OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA.
The next generation in cancer therapies will be more targeted with less side effects. At OncoSenX we believe the battle against cancer should be fought with genetic information. Our treatment delivers a simple program that induces apoptosis in cancerous cells. Our approach is a less invasive, more precise intervention for this complex and devastating disease. The next generation of cancer therapies has begun...
Our system is comprised of two main components: An untargeted non-toxic lipid nanoparticle and a highly targeted DNA payload.
DNA plasmids encode an inducible death protein under a promoter that is active in the target cell population. We are initially targeting cells that are transcriptionally active for p53.
Cells are killed via apoptosis with caspase 9.
We can use our DNA payload to effectively implement logic gates (IF/OR/AND). This allows us to precisely target cell populations based on their genetic activity without harming adjacent cells.
Our patented lipid nanoparticle (LNP) is the transfection agent that efficiently delivers our non-integrating DNA plasmid to cancer cells
These LNPs have been shown to be non-immunogenic, even with adjuvant, and are non-toxic at doses up to 10x expected human therapeutic dose in rodents and non-human primates.
Anti-LNP antibody & neutralization assays:
- Virtually no antibody response to LNPs in immune-competent mice, even with adjuvants
- Neutralization requires very high antibody concentration
- “Vaccination” against LNPs does not reduce efficacy
- Repeat dosing is effective and well tolerated
LNPs is generally less reactive than other lipid drug formulations
Non-Human Primate Studies were Initiated late August, 2017 by RxGen and concluded mid-September. Analysis is still underway but no visible toxicity is seen in animals receiving full treatment course at ten times the normal human dose.
Oisín Biotechnologies' ground-breaking research and technology is demonstrating that the solution to mitigating the effects of age-related diseases is to address the damage created by the aging process itself.
Entos Pharmaceuticals is a healthcare biotechnology company that develops precision breakthrough therapies through strategic development partnerships.
The Methuselah Fund is designed to accelerate results in the longevity field, extending the healthy human lifespan. Their success is measured by financial return on investments and furthering the mission, with the mission being the priority. Their network of mission-oriented individuals contains many angels, super-angels and professional investors.
The Methuselah Foundation is a forward thinking medical public non-profit Foundation that looks for, examines, carefully tests, and implements high-leverage interventions that spur concrete progress in the short term and causes synergistic ripple effects over time in the longevity and health-span field.
The SENS Research Foundation conducts research that emphasizes the application of regenerative medicine to age-related disease, with the intent of repairing underlying damage to the body's tissues, cells, and molecules. Its goal is to help build the industry that will cure the diseases of aging.
UNIVERSITY OF ALBERTA, CANADA
The Lewis lab at the University of Alberta utilizes real-time intravital imaging of the tumour microenvironment to learn about the critical steps of cancer progression, including the growth of new blood vessels and the gain of tumor cell motility that leads to metastasis. It is investigating novel nanoparticles that are being developed for the early detection of prostate cancer, drug delivery, and the in vivo study of tumor cell invasion and metastasis.
800 5th Avenue, Suite 4100
Seattle, WA 98104